Panova I E, Titov A V, Mirsaitova D R
St. Petersburg branch of S.N. Fyodorov National Medical Research Center «MNTK «Eye Microsurgery», St. Petersburg, Russia.
Vestn Oftalmol. 2020;136(4):110-116. doi: 10.17116/oftalma2020136041110.
To analyze the effectiveness of artificial tear drops Thealoz (trehalose 3%) in the correction of dry eye syndrome (DES) after ReLEx SMILE and FEMTO LASIK keratorefractive surgeries.
The study included 20 patients (40 eyes) who underwent a keratorefractive surgery and were prescribed instillations of Thealoz artificial tear drops for the correction of dry eye syndrome. Patients were divided into 2 group: the 1 group consisted of 10 patients who underwent ReLEx SMILE surgery, the 2nd group - 10 patients after FEMTO LASIK. The effectiveness of the treatment was evaluated at 1 and 3 months after the surgery using Ocular Surface Disease Index (OSDI), changes in the anterior corneal epithelium (Oxford scale), and tear break-up time (Norn's test).
It was found that the use of artificial tear drops Thealoz regardless of the type of keratorefractive surgery helps reduce discomfort based on the OSDI questionnaire from 10.90±4.55 to 10.20±4.07 and 8.89±3.26 points by 1 and 3 months of the follow-up, respectively (≤0.05). The degree of epitheliopathy according to the Oxford scale decreases from 0.73±0.75 to 0.25±0.43 points 3 months after the surgery (≤0.05), which is accompanied by a significant increase in tear break-up time (Norn's test) from 11.18±1.19 to 12.43±1.03 and 12.45±1.03 seconds 1 and 3 months after treatment, respectively (≤0,05).
Complex evaluation of the ocular surface has proved that artificial tear drops Thealoz is effective in reducing DES manifestations after keratorefractive surgery. The results clearly demonstrate that the drug helps increase stability of the tear break-up time, as well as contributes to the decrease in epitheliopathy and subjective discomfort sensations, giving grounds to widen its use in clinical practice.
分析人工泪液Thealoz（3%海藻糖）对ReLEx SMILE和飞秒激光原位角膜磨镶术（FEMTO LASIK）后干眼综合征（DES）的矫正效果。
该研究纳入20例（40只眼）接受角膜屈光手术并被处方使用Thealoz人工泪液以矫正干眼综合征的患者。患者分为两组：第一组由10例行ReLEx SMILE手术的患者组成，第二组为10例飞秒激光原位角膜磨镶术后患者。在术后1个月和3个月时，使用眼表疾病指数（OSDI）、角膜前上皮变化（牛津量表）和泪膜破裂时间（诺恩试验）评估治疗效果。
研究发现，无论角膜屈光手术类型如何，使用人工泪液Thealoz均有助于减轻不适。根据OSDI问卷，随访1个月和3个月时，不适评分分别从10.90±4.55降至10.20±4.07以及从8.89±3.26降至更低（P≤0.05）。术后3个月，牛津量表评估的上皮病变程度从0.73±0.75降至0.25±0.43分（P≤0.05），同时泪膜破裂时间（诺恩试验）显著延长，治疗后1个月和3个月时分别从11.18±1.19秒增至12.43±1.03秒以及从11.18±1.19秒增至12.45±1.03秒（P≤0.05）。
眼表的综合评估证明，人工泪液Thealoz在减轻角膜屈光手术后干眼综合征表现方面有效。结果清楚表明，该药物有助于提高泪膜破裂时间的稳定性，同时有助于减轻上皮病变和主观不适感觉，为其在临床实践中的更广泛应用提供了依据。
